An Open-label, Single Dose, Parallel-group Study to Evaluate the Pharmacokinetics of LCQ908 in Patients With Mild, Moderate and Severe Hepatic Impairment Compared to Age, Gender and Weight-matched Healthy Volunteers.

Trial Profile

An Open-label, Single Dose, Parallel-group Study to Evaluate the Pharmacokinetics of LCQ908 in Patients With Mild, Moderate and Severe Hepatic Impairment Compared to Age, Gender and Weight-matched Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2015

At a glance

  • Drugs Pradigastat (Primary)
  • Indications Coronary artery disease; Hyperlipidaemia; Obesity; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Nov 2012 Planned End Date changed from 1 Dec 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 15 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top